Not intended for U.S. and U.K. Media Berlin, January 10, 2023 – On the occasion of the 41st J.P. Morgan Healthcare conference in San Francisco, Bayer AG announced it is raising its combined peak sales forecast for key growth drivers in its pharma portfolio to over twelve billion euros. This improved outlook comes amid the …
Nov. 28, 2023 — The “sunscreen paradox” has confounded doctors of late: As more and more people use sunscreen, rates of melanoma and other skin cancers are going up. The statistics on all types of skin cancer are sobering: Invasive melanoma cases diagnosed annually increased 27% over the past 10 years. The rate of basal …
You May Be Increasing Your Skin Cancer Risk Without Knowing It Read More »
Nov. 27, 2023 — On a drizzly Wednesday afternoon, Christopher sat in an overstuffed reclining chair, relaxing with a cozy blanket draped across him after his most recent infusion at the Ketamine Healing Clinic of Los Angeles. Diagnosed with depression at age 19, Christopher (not his real name), now a 35-year-old graduate student, has struggled …
Soaring Use of Ketamine Creates a Health Care ‘Wild West’ Read More »
By Sharon Solomon, MD, as told to Keri Wiginton Geographic atrophy (GA) is an advanced dry form of age-related macular degeneration (AMD). Up to 20% of folks with AMD may get it. While we see GA across all populations and races, it’s more common in older folks who have a family history of AMD and …
Credit: CC0 Public Domain Walking at a speed of 4 or more km an hour is linked to a significantly lower risk of type 2 diabetes, suggests a pooled data analysis of the available evidence, published online in the British Journal of Sports Medicine. Moreover, the faster the speed above 4 km/hour, the lower the …
Faster walking speed of 4 km+/hour linked to significantly lower type 2 diabetes risk Read More »
Dr. Carolina Garcia in the laboratory with Dr. Cullen Taniguchi. Credit: The University of Texas MD Anderson Cancer Center A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective …
Leverkusen, April 28, 2023 – Bayer strengthened its position as a successful life science company in 2022 despite the difficult conditions. “We now need to build on these strong foundations and set the course for future growth,” CEO Werner Baumann said at the company’s virtual Annual Stockholders’ Meeting in Leverkusen on Friday. “The need is …
01 March 2023 | 07:59 AM Europe/Amsterdam Not intended for U.S. and UK Media Summary Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and …
Bayer submits aflibercept 8 mg for marketing authorization in Japan Read More »
Not intended for U.S. and UK Media Berlin, March 1, 2023 – The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is …
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer Read More »
Leverkusen, February 28, 2023 – The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the challenging environment. We were able to deliver, even during these difficult times, and met the upgraded financial targets we set in August,” said Werner Baumann, Chairman …